Medyria
not stated, CH · 6 known investors
Find your way into Medyria
Medyria addresses the diagnosis of angina pectoris, focusing on coronary conditions such as Coronary Artery Disease (CAD) and Non-Obstructive Coronary Artery Disease (NOCAD) linked to coronary microvascular dysfunction. The company positions itself around cardiovascular diagnostics where standard tests fail to identify NOCAD and CMD patients in time.
Investors · 6
Also in the syndicate · 4
EFI-Lake Geneva VenturesStart Angels NetworkYellowstone Holding AGleadZürcher Kantonalbank
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BMar 2023
Yellowstone Holding AG (lead), EFI-Lake Geneva Ventures, Start Angels Network, Zürcher Kantonalbank
Source ↗ - Undisclosed amountSeries BJan 2023
Yellowstone Holding AG (lead), EFI-Lake Geneva Ventures, Start Angels Network, Zürcher Kantonalbank
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Medyria do?
- Medyria addresses the diagnosis of angina pectoris, focusing on coronary conditions such as Coronary Artery Disease (CAD) and Non-Obstructive Coronary Artery Disease (NOCAD) linked to coronary microvascular dysfunction. The company positions itself around cardiovascular diagnostics where standard tests fail to identify NOCAD and CMD patients in time.
- Who are Medyria's investors?
- Medyria's investors include StartAngels Network, Venture Kick.
- Where is Medyria headquartered?
- Medyria is headquartered in not stated, CH.